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Therapy With Interferon-α Plus Ribavirin for Membranoproliferative
Glomerulonephritis Induced by Hepatitis C Virus
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A. Eduardo B. Silva1, Gianna Mastroianni Kirsztajn2, Department of Medicine, São Paulo Medical School,
Cibele N. Cruz1 and Maria Lucia G Ferraz1 Federal University of São Paulo, São Paulo, SP, Brazil
We describe a treatment made with interferon-α (IFN-α) plus ribavirin of two patients with
membranoproliferative glomerulonephritis (MPGN) induced by hepatitis C virus (HCV): Case 1
was a 22-year-old woman with leg and facial edema, hypertension and proteinuria, whose liver
biopsy revealed chronic active hepatitis; and Case 2 was a 42-year-old man with anasarca,
hypertension and proteinuria, whose liver biopsy indicated cirrhosis. Both had anti-HCV, HCV-
RNA and cryoglobulins. IFN-α (3 million units (MU), 3 times/week) and ribavirin (1 g/day) were
administered for 12 months. The drugs were well tolerated by both patients. Serum alanine
aminotransferase (ALT) levels normalized and HCV-RNA became negative. Cryoglobulins
disappeared and an improvement in renal disease was seen after 6 months of therapy. However,
after 9 months, Case 2 presented ALT elevation, and proteinuria was detected. Two years after the
end of therapy, both patients were negative in repeated HCV-RNA and cryoglobulin tests. Case 1
was asymptomatic, with normal liver and renal tests, and Case 2 had normal blood pressure, with
mild edema of the ankles. Based on the evolution of these two cases, the association of IFN-α and
ribavirin may be a therapeutic option for patients with MPGN related to HCV.
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Hepatitis C virus (HCV) is associated with several
extrahepatic manifestations. Mixed cryoglobulinemia
(MC) is the most common, being detected in about
50% of the cases [1,2]. Some researchers have
reported that approximately 15% of patients with
HCV and MC also present glomerulonephritis,
particularly membranoproliferative glomerulonephritis
(MPGN) [2-5].
In adults, most patients with primary or secondary
MPGN have a poor outcome, progressing to renal failure
[6]. The diagnosis of a secondary disease in patients
with glomerulonephritis assumes special importance,
particularly in the cases of HCV infection, since it can
lead to changes in the therapeutic approach. In fact,
protocols of treatment of glomerulonephritis induced by
HCV, using interferon-α (IFN-α), have produced
remission of proteinuria, concomitantly with virological
response during therapy, but a high rate of relapse of
liver and kidney diseases was observed after stopping
drug usage [7, 8]. Other studies have also shown clinical
improvement in patients with MPGN induced by HCV
during treatment with ribavirin, but recurrence occurred
in almost all patients after drug discontinuation [9, 10].
During the last few years, some trials have
demonstrated that the administration of IFN-α plus
ribavirin to patients with chronic hepatitis C infections
gives much better results than those observed with the
use of each one alone [11].  In fact, Misiani et al. [12]
and Garini et al. [13] described a good response by
three patients who were treated with a combination of
IFN plus ribavirin for HCV-induced MPGN. We
describe here two more patients with MPGN induced
by HCV who had improvement of hepatic and renal
diseases after treatment with IFN-α plus ribavirin.
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Case Reports
Case 1.  A 22-year-old woman, with a history of
edema of the legs and face since 2 months before
admission, who used furosemide and nifedipine daily,
was referred for evaluation. On physical examination,
she presented edema and hypertension (180/100 mm
Hg). Her medical history was unremarkable, but she
had received a blood transfusion 21 years before. The
main laboratory data were: 2.5 g/day proteinuria,
numerous dysmorphic erythrocytes in the urine (100
red blood cells per high-power field) and 1.3 mg/dL
serum creatinine. Serum alanine aminotransferase was
mildly elevated (alanine aminotransferase (ALT) = 35
U/mL; AST normal), anti-HCV antibodies and HCV-
RNA were both positive, and the HCV genotype was
1b. HBV markers were negative. The serum levels of
cryoglobulins were 243 ηg/mL (type II). Renal biopsy
revealed MPGN, and the liver biopsy showed chronic
active hepatitis. Treatment with IFN-α plus ribavirin
was indicated.
Case 2.  A 42-year-old man with a history of edema
of the legs that progressed to anasarca during the
previous 3 months was referred. The patient was
previously an intravenous drug addict. On physical
examination, he presented anasarca and hypertension
(150/100 mm Hg). The main laboratory data were: 1.3
g/day proteinuria, numerous dysmorphic erythrocytes in
urine (100 red blood cells per high-power field) and 1.9
mg/dL serum creatinine. Serum aminotransferases were
elevated (ALT = 53 U/mL; AST = 60 U/mL); anti-HCV
antibodies and HCV-RNA were both positive, and the
HCV genotype was 3a. The serum levels of cryoglobulins
were 186 ηg/mL (type II). Renal biopsy revealed MPGN
and the liver biopsy showed active cirrhosis. It was decided
to treat him with IFN-α plus ribavirin.
Materials and Methods
Anti-HCV antibodies were measured using a
second-generation enzyme immunoassay (Abbott
Laboratories) and the serum HCV-RNA was
investigated using a nested-PCR, as described by
Shindo et al. [14]. Genotyping was performed by
sequence analysis of a portion of the 5' untranslated
region of the HCV genome [15]. Cryoglobulins were
identified by immunoelectrophoresis, with specific
antibodies against immunoglobulins, and quantified by
the Lowry method. In both cases, other possible causes
of glomerulonephritis were excluded, such as diabetes,
systemic lupus erythematosus, lues, schistosomiasis
mansoni, and malignancies.
Three million units (MU) of IFN-α 2b were
administered subcutaneously, 3 times a week, and 1 g/
day of ribavirin was taken orally, both during 12 months.
The patients were evaluated monthly during the
treatment and were followed up till 24 months after the
end of therapy.
Results
Both patients tolerated well the combination therapy.
There was a slight decrease in the hemoglobin levels
and a rise in the number of reticulocytes, which
normalized spontaneously after treatment was
completed. After the beginning of the therapy, Case 1
had a regression of the edemas and gradual control of
blood pressure levels, allowing the interruption of
antihypertensive drugs. At the third month of therapy,
she presented normalization of ALT serum levels, HCV-
RNA became negative, and cryoglobulins and
proteinuria levels decreased (Figure 1).
These parameters persisted without significant
changes until the end of therapy. At 24 months after
stopping therapy, she continued to be asymptomatic,
without using any medication; serum ALT levels were
normal, cryoglobulins and HCV-RNA test were
negative. There were also no urinary abnormalities.
Contraceptive methods were stopped and the patient
became pregnant.
After the beginning of therapy, Case 2 had reduced
edema, and he needed less antihypertensive drugs. By
the sixth month, he had normal serum aminotransferase
levels, the HCV-RNA test became negative, and serum
levels of cryoglobulins and proteinuria decreased.
However, by the ninth month, the levels of
aminotransferases increased and proteinuria was
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Figure 1. Laboratory data of Case 1 of hepatitis C virus-induced membranoproliferative glomerulonephritis
during therapy with interferon-α (3 million units, 3 times a week) plus ribavirin (1g/day), and follow-up. Serum
levels of alanine aminotransferase (ALT) and cryoglobulinemia are expressed as the value above the upper limit
of normal; proteinuria is expressed as g/24 hours.
Figure 2. Laboratory data of Case 2 during therapy with interferon-α (3 million units, 3 times a week) plus
ribavirin (1g/day) and follow-up. Serum levels of alanine aminotransferase (ALT) and cryoglobulinemia are
expressed as the value above the upper limit of normal; proteinuria is expressed as g/24 hours.
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detected, although cryoglobulinemia and HCV-RNA
remained negative (Figure 2). Twenty-four months
after the end of the therapy, he presented a mild edema
of ankles and his hypertension was under control,
using 25 mg/day spironolactone. The serum AST was
mildly elevated (52 U/mL), HCV-RNA and
cryoglobulinemia were negative, and proteinuria was
still present (1.1 g/day).
Discussion
IFN-α has antiviral activity and it is being used in
the management of viral hepatitis, as well as in the
treatment of the extrahepatic manifestations related to
HCV [7,11]. However, long-term biochemical,
virological and histological improvements with the use
of IFN-α alone is observed in less than 20% of patients
[11]. In fact, Johnson et al. [7] treated 14 patients who
had chronic active hepatitis C and MPGN with IFN-
α, and observed a decrease in proteinuria as well as in
serum aminotransferases and viremia. But the favorable
effect of this therapy was observed only during the drug
administration period. Sarac et al. [16] treated a patient
with cryoglobulinemic MPGN, induced by HCV, with
high doses of IFN-α (10 MU daily, during 2 weeks,
followed by 10 MU on alternate days during more 6
weeks); The patient  still had a virological response a
year after the end of the therapy. A second renal biopsy
showed histological improvement. The authors
suggested that is possible to reach and maintain
hepatic and renal improvement with high doses of
IFN-α, though this is frequently poorly tolerated.
Additionally, Wilson [17] described the benefit of
long-term IFN-α therapy, during 5 years, for
symptomatic mixed cryoglobulinemia in a patient with
cutaneous vasculitis and MPGN induced by hepatitis
C. He reported that therapy with interferon for a long
period is effective, however the patient developed
several side effects.
Given the limited results using only IFN-α in the
treatment of hepatitis C, other drugs have been
proposed, such as ribavirin, a guanosine analog with
antiviral activity. In trials involving patients with chronic
hepatitis C, the use of ribavirin decreased serum levels
of ALT, but relapses occurred after stopping the drug
[18, 19]. Moreover, we treated a patient with HCV-
induced cryglobulinemic MPGN with ribavirin alone,
and observed an improvement of hepatic and renal
disease at the end of the treatment. However, 2
months after the end of the treatment, there was a
new increase in proteinuria, and the ALT levels
became similar to those before treatment [9]. In
addition, Pham et al. treated 4 patients submitted to
liver transplantation, who presented nephrotic
syndrome secondary to HCV-related MPGN, with
ribavirin alone. They observed a decrease in
proteinuria in the 4 cases, but after the drug treatment
was stopped, proteinuria recurred in 2 patients. After
reintroduction of ribavirin, the patients again showed
a favorable response [10].
Nowadays, several studies suggest that an
association of these two drugs, IFN-α and ribavirin,
amplifies their therapeutic effects against HCV and
leads to a higher frequency of sustained response,
around 40% [11, 20]. Additionally, it is generally agreed
that the initial therapy of chronic hepatitis C should be
made with IFN-α plus ribavirin [20]. Recently, the first
case of MPGN induced by HCV was reported to be
successful treated with this combination [12].
We followed two other patients who were
submitted to therapy with IFN-α plus ribavirin (this
study).  A sustained response was observed in Case
1 during 24 months after the treatment was stopped.
The other patient had an adequate response during
the first 9 months of therapy but subsequently
proteinuria and a rise in serum aminotransferases were
observed. However, he experienced clinical
improvement of the edema and systemic hypertension.
Twenty-four months after the end of the treatment,
the patient maintained a discreet edema of the ankles,
using only a small dose of diuretic, with no signs of
cryoglobulins and was negative for serum HCV-RNA.
Our experience with these patients lead us to believe
that IFN-α plus ribavirin is a useful alternative
treatment for the management of HCV-induced
MPGN. Further studies with more patients, or using
pegylated IFN-α, should be carried out to determine
the true benefit of this therapy.
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